La présentation est en train de télécharger. S'il vous plaît, attendez

La présentation est en train de télécharger. S'il vous plaît, attendez

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease  Aurelien Amiot, Jean-Charles Grimaud, Laurent.

Présentations similaires


Présentation au sujet: "Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease  Aurelien Amiot, Jean-Charles Grimaud, Laurent."— Transcription de la présentation:

1 Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease  Aurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Jerome Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefanescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaud Vaysse, Anne Bourrier, Stephane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephanie Viennot, Alexandre Aubourg, Anne-Laure Pelletier, Guillaume Bouguen, Vered Abitbol, Yoram Bouhnik Aurelien Amiot, Charlotte Gagniere, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Camille Zallot, Marc-Andre Bigard, Jerome Filippi, Xavier Hebuterne, Benjamin Pariente, Maria Nachury, Pierre Desreumaux, Xavier Roblin, Emilie Del Tedesco, Anthony Buisson, Gilles Bommelaer, Carmen Stefanescu, Arnaud Boureille, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Xavier Dray, Franck Carbonnel, Philippe Seksik, Laurent Beaugerie, Jacques Cosnes, Harry Sokol, Cecilia Landman, Stephane Nancey, Gilles Boschetti, David Laharie, Florian Poullenot, Matthieu Allez, Jean-Marc Gornet, Clautilde Baudry, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephane Koch, Stephanie Viennot, Alexandre Aubourg, Laurence Picon, Anne-Laure Pelletier, Gaelle Sickersen, Guillaume Bouguen, Vered Abitbol, Stanislas Chaussade, Yoram Bouhnik, Stephane Nahon, Betsy Winkfield, Hedia Brixi-Benmansour, Rodica Gincul, Jean- Christophe Barberis, Bruno Bonaz, Christophe Michiels, Franck Zerbib, Marie Bourrier de Beauregard, Christophe Locher, Sophie Davin- Couve, Armelle Poirette, Laurence Guillem, Monica Stetiu-Mocanu, Sylvain Beorchia, Jawad Al Qaddi Aurelien Amiot, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Jerome Filippi, Benjamin Pariente, Xavier Roblin, Anthony Buisson, Carmen Stefanescu, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Thibaud Vaysse, Anne Bourrier, Stephane Nancey, David Laharie, Matthieu Allez, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephanie Viennot, Alexandre Aubourg, Anne-Laure Pelletier, Guillaume Bouguen, Vered Abitbol, Yoram Bouhnik Aurelien Amiot, Charlotte Gagniere, Jean-Charles Grimaud, Laurent Peyrin-Biroulet, Camille Zallot, Marc-Andre Bigard, Jerome Filippi, Xavier Hebuterne, Benjamin Pariente, Maria Nachury, Pierre Desreumaux, Xavier Roblin, Emilie Del Tedesco, Anthony Buisson, Gilles Bommelaer, Carmen Stefanescu, Arnaud Boureille, Caroline Trang-Poisson, Romain Altwegg, Philippe Marteau, Xavier Dray, Franck Carbonnel, Philippe Seksik, Laurent Beaugerie, Jacques Cosnes, Harry Sokol, Cecilia Landman, Stephane Nancey, Gilles Boschetti, David Laharie, Florian Poullenot, Matthieu Allez, Jean-Marc Gornet, Clautilde Baudry, Guillaume Savoye, Jacques Moreau, Charlotte Gagniere, Lucine Vuitton, Stephane Koch, Stephanie Viennot, Alexandre Aubourg, Laurence Picon, Anne-Laure Pelletier, Gaelle Sickersen, Guillaume Bouguen, Vered Abitbol, Stanislas Chaussade, Yoram Bouhnik, Stephane Nahon, Betsy Winkfield, Hedia Brixi-Benmansour, Rodica Gincul, Jean-Christophe Barberis, Bruno Bonaz, Christophe Michiels, Franck Zerbib, Marie Bourrier de Beauregard, Christophe Locher, Sophie Davin-Couve, Armelle Poirette, Laurence Guillem, Monica Stetiu-Mocanu, Sylvain Beorchia, Jawad Al Qaddi  Clinical Gastroenterology and Hepatology  Volume 14, Issue 11, Pages e2 (November 2016) DOI: /j.cgh Copyright © 2016 AGA Institute Terms and Conditions

2 Figure 1 Outcome measures at week 14 for vedolizumab therapy in patients with (A) Crohn’s disease and (B) ulcerative colitis. *P value less than .005 when comparing week 6 and week 14 efficacy results. Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh ) Copyright © 2016 AGA Institute Terms and Conditions

3 Figure 2 Changes in the (A) Harvey–Bradshaw Index, (B) partial ulcerative colitis disease activity index, and (C) C-reactive protein level at baseline and at weeks 6 and 14 after vedolizumab therapy was started. Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh ) Copyright © 2016 AGA Institute Terms and Conditions

4 Supplementary Figure 1 Changes according to the presence of steroid-free clinical remission at week 14 according to the (A) Harvey–Bradshaw Index, (B) partial ulcerative colitis disease activity index, and (C) C-reactive protein level at baseline and at weeks 6 and 14 after vedolizumab therapy was started. Clinical Gastroenterology and Hepatology  , e2DOI: ( /j.cgh ) Copyright © 2016 AGA Institute Terms and Conditions


Télécharger ppt "Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease  Aurelien Amiot, Jean-Charles Grimaud, Laurent."

Présentations similaires


Annonces Google